ProMIS Neurosciences, Inc. (PMN)

NCM – Real Time Price. Currency in USD

10.49

-0.19 (-1.78%)

At close: May 12, 2026, 4:00 PM EDT

10.92

+0.43 (4.10%)

Pre-market: May 13, 2026, 4:31 AM EDT

12.05.2026

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

Cambridge, Massachusetts, May 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update.

13.04.2026

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer, will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference. The conference is being held April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Ontario.

25.03.2026

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced its financial results for the year ended December 31, 2025, and provided a corporate update.

18.03.2026

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

Cambridge, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer's & Parkinson's Diseases Conference (AD/PD™ 2026), being held March 17–21, 2026 in Copenhagen, Denmark. The posters will highlight ongoing research related to the Company's proprietary discovery platform and its approach to selectively targeting toxic misfolded proteins in neurodegenerative diseases.

04.02.2026

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12th, 2026 in New York, NY. The fireside chat will be held at 9:30am Eastern Time on Wednesday, February 11th and a live webcast of the presentation may be accessed by visiting the Events page of the Company's website at www.promisneurosciences.com.

30.01.2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS' landmark Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-2026; 12-month top-line data expected toward end of 2026 CAMBRIDGE, Massachusetts , Jan. 30, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors to issue and sell up to an aggregate of approximately $175 million comprised of (i) 6,815,296 common shares, no par value (the “Common Shares”), (ii) Common Share Warrants to purchase 6,915,296 Common Shares or Pre-Funded Warrants in lieu thereof (the “Common Share Warrants”), and (iii) Pre-Funded Warrants to purchase 100,000 Common Shares (the “Pre-Funded Warrants”, and the Common Shares issuable upon exercise of the Common Share Warrants and Pre-Funded Warrants, the “Warrant Shares”). 6,090,075 Common Shares were sold at a price of $10.77 per Common Share, 100,000 Pre-Funded Warrants were sold at a price of $10.77 less an exercise price $0.0001 per Warrant Share and 725,221 Common Shares were sold at a price of $12.13 per Common Share to certain affiliates and insiders of the Company.

18.12.2025

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's disease

Videos

No Data

There is no data to display

Press releases

12.05.2026

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

25.03.2026

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

04.02.2026

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

30.01.2026

ProMIS Neurosciences, Inc. (PMN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ProMIS Neurosciences, Inc. (PMN)

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Videos

No Data

Press releases

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Videos

No Data

Press releases

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Search stocks

ProMIS Neurosciences, Inc. (PMN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ProMIS Neurosciences, Inc. (PMN)

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Videos

No Data

Press releases

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Videos

No Data

Press releases

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing